Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG141 in Treated Chronic Hepatitis B with Low Viremia
NCT05637541Phase 2Completed
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of narecovir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Serum HBV DNA at 24 weeks. Started Jan 2023; status: completed.
02
Drugs
narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05637541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637541.